By combining all three receptor targets, Retatrutide allows researchers to study the convergence of incretin biology and glucagon-driven energy expenditure in a single compound, opening research questions that cannot be addressed with any dual or single-receptor agonist
Dr Cheah Ming Hann, a family physician at National University Polyclinics, said that obesity is increasingly recognised as a chronic disease and that many patients do not realise that weight regain is common once treatment stops
We source the highest quality, deep, cold-water fish using traditional, sustainable methods
Front Endocrinol 13:1027237
The studies were conducted in a variety of countries (USA, Sweden, Germany, Denmark, and China), which increased the generalizability of the findings across populations
doi: 10.1038/s41467-024-44994-w